A detailed history of Bank Of America Corp transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 92,043 shares of RYTM stock, worth $5.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,043
Previous 111,114 17.16%
Holding current value
$5.9 Million
Previous $4.81 Million 21.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$35.41 - $44.37 $675,304 - $846,180
-19,071 Reduced 17.16%
92,043 $3.78 Million
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $1.61 Million - $2.16 Million
41,244 Added 59.03%
111,114 $4.81 Million
Q4 2023

Feb 14, 2024

SELL
$21.39 - $49.64 $1.5 Million - $3.49 Million
-70,248 Reduced 50.13%
69,870 $3.21 Million
Q2 2023

Aug 14, 2023

SELL
$16.32 - $21.15 $3.58 Million - $4.64 Million
-219,548 Reduced 61.04%
140,118 $2.31 Million
Q1 2023

May 12, 2023

BUY
$16.88 - $34.24 $1.58 Million - $3.2 Million
93,513 Added 35.14%
359,666 $6.42 Million
Q4 2022

Feb 10, 2023

BUY
$22.21 - $30.25 $1.06 Million - $1.44 Million
47,744 Added 21.86%
266,153 $7.75 Million
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $727,977 - $5.22 Million
169,297 Added 344.72%
218,409 $5.35 Million
Q2 2022

Aug 12, 2022

BUY
$3.12 - $12.25 $29,630 - $116,338
9,497 Added 23.97%
49,112 $203,000
Q1 2022

May 16, 2022

SELL
$6.13 - $12.24 $508,912 - $1.02 Million
-83,020 Reduced 67.7%
39,615 $457,000
Q4 2021

Feb 08, 2022

SELL
$8.62 - $13.9 $705,357 - $1.14 Million
-81,828 Reduced 40.02%
122,635 $1.22 Million
Q3 2021

Nov 15, 2021

BUY
$11.68 - $20.72 $990,288 - $1.76 Million
84,785 Added 70.84%
204,463 $2.67 Million
Q2 2021

Sep 13, 2021

BUY
$18.52 - $22.55 $2.22 Million - $2.7 Million
119,678 New
119,678 $2.34 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.57B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.